(24/7 MARKET NEWS) – Biocept, Inc. (BIOC:NASDAQ) announced, this morning, that it signed a non-exclusive licensing agreement for CNSide™ with Plus Therapeutics, Inc. (PSTV:NASDAQ), expanding the two companies’ June 2022 comprehensive laboratory services agreement. Plus is using CNSide, Biocept’s proprietary cerebrospinal fluid (CSF)-based tumor cell capture and enumeration platform, in a clinical trial with their targeted radiotherapeutic to treat patients with carcinomas and/or melanomas with suspected leptomeningeal metastases (LM), which is cancer in the membranes that surround the brain and spinal cord.
Biocept is trading at $0.94, up $0.0996 (+11.85%), on 22.24K premarket shares traded.
Its 52-week range is $0.80 to $29.55. Today’s volume is the key to this one, as there’s not much high volume resistance after $1.25 and it could even challenge the gap.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
